Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Basic Description
| Synonyms | DTXSID8021640 | Opera_ID_740 | Spectrum3_000278 | Azelex | Finacea Foam | MLS000069659 | Acido azelaico | MLS001148615 | Emerox 1110 | Finevin | KBioGR_000662 | Lopac0_000051 | Nonandisaure | Spectrum5_001304 | Anchoate | SR-01000075671 | 1,7-Dicarboxyhep |
|---|---|
| Specifications & Purity | Moligand™, technical grade, ≥85%(GC) |
| Shipped In | Normal |
| Grade | Moligand™, technical grade |
Product Properties
| ALogP | 1.6 |
|---|
Associated Targets(Human)
CYP1A2 Tchem Cytochrome P450 1A2 (0 Activities)
CYP1B1 Tchem Cytochrome P450 1B1 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
CNR1 Tclin Cannabinoid receptor 1 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
CYP2C19 Tchem Cytochrome P450 2C19 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
DRD2 Tclin D(2) dopamine receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
CYP3A4 Tclin Cytochrome P450 3A4 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ESR1 Tclin Estrogen receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
GABRA1 Tclin Gamma-aminobutyric acid receptor subunit alpha-1 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
EHMT2 Tchem Histone-lysine N-methyltransferase EHMT2 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
NR3C1 Tclin Glucocorticoid receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
AVPR1A Tclin Vasopressin V1a receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
HDAC6 Tclin Histone deacetylase 6 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
HRH1 Tclin Histamine H1 receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
SLCO1B1 Tchem Solute carrier organic anion transporter family member 1B1 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
SLC6A3 Tclin Sodium-dependent dopamine transporter (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
SLC6A4 Tclin Sodium-dependent serotonin transporter (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
PDE4D Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4D (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
PDE3A Tclin cGMP-inhibited 3',5'-cyclic phosphodiesterase A (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
PTGS1 Tclin Prostaglandin G/H synthase 1 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
PTGS2 Tclin Prostaglandin G/H synthase 2 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
CACNA1C Tclin Voltage-dependent L-type calcium channel subunit alpha-1C (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
DRD3 Tclin D(3) dopamine receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
CHRM3 Tclin Muscarinic acetylcholine receptor M3 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ADRA2B Tclin Alpha-2B adrenergic receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ADRA2C Tclin Alpha-2C adrenergic receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
APEX1 Tchem DNA-(apurinic or apyrimidinic site) lyase (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
HTR2A Tclin 5-hydroxytryptamine receptor 2A (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ADORA2A Tclin Adenosine receptor A2a (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ADRA2A Tclin Alpha-2A adrenergic receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ADRB1 Tclin Beta-1 adrenergic receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ADRA1A Tclin Alpha-1A adrenergic receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
AR Tclin Androgen receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
MAOA Tclin Amine oxidase [flavin-containing] A (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
HTR2C Tclin 5-hydroxytryptamine receptor 2C (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ADORA1 Tclin Adenosine receptor A1 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
HTR1A Tclin 5-hydroxytryptamine receptor 1A (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ADORA3 Tchem Adenosine receptor A3 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
HTR3A Tclin 5-hydroxytryptamine receptor 3A (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
HTR2B Tclin 5-hydroxytryptamine receptor 2B (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
OPRD1 Tclin Delta-type opioid receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
OPRK1 Tclin Kappa-type opioid receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
OPRM1 Tclin Mu-type opioid receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
MLNR Tchem Motilin receptor (0 Activities)
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
ESR1 Tclin Estrogen receptor alpha (17718 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PGR Tclin Progesterone receptor (8562 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
AR Tclin Androgen Receptor (11781 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
TSHR Tclin Thyroid stimulating hormone receptor (29986 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MAOA Tclin Monoamine oxidase A (11911 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HRH2 Tclin Histamine H2 receptor (5428 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
AGTR1 Tclin Type-1 angiotensin II receptor (5176 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SLC6A4 Tclin Serotonin transporter (12625 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HRH1 Tclin Histamine H1 receptor (7573 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
OPRM1 Tclin Mu opioid receptor (19785 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
OPRD1 Tclin Delta opioid receptor (15096 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SLC6A3 Tclin Dopamine transporter (10535 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
GRIN1 Tclin Glutamate (NMDA) receptor subunit zeta 1 (122 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
KCNH2 Tclin HERG (29587 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CACNA1C Tclin Voltage-gated L-type calcium channel alpha-1C subunit (766 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PDE3A Tclin Phosphodiesterase 3A (3309 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1711 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADRA2C Tclin Alpha-2c adrenergic receptor (4876 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CHRM3 Tclin Muscarinic acetylcholine receptor M3 (7750 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR2B Tclin Serotonin 2b (5-HT2b) receptor (10323 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
TBXA2R Tclin Thromboxane A2 receptor (5717 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADORA2A Tclin Adenosine A2a receptor (16305 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADORA3 Tchem Adenosine A3 receptor (15931 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
BDKRB2 Tclin Bradykinin B2 receptor (3970 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CHRNA4 Tclin Neuronal acetylcholine receptor protein alpha-4 subunit (1265 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ARSA Tbio Cerebroside-sulfatase (655 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
ampC Beta-lactamase AmpC (62480 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mc4r Melanocortin receptor 4 (1205 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Npy1r Neuropeptide Y receptor type 1 (8 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Cckar Cholecystokinin A receptor (90 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Pde4d Phosphodiesterase 4D (4 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Hdac6 Histone deacetylase 6 (222 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
rep Replicase polyprotein 1ab (378 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
pfk 6-phospho-1-fructokinase (7870 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ffp 4'-phosphopantetheinyl transferase ffp (24982 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
FTL Ferritin light chain (43324 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SARS-CoV-2 (38078 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Names and Identifiers
| IUPAC Name | nonanedioic acid |
|---|---|
| INCHI | InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13) |
| InChi Key | BDJRBEYXGGNYIS-UHFFFAOYSA-N |
| Canonical SMILES | C(CCCC(=O)O)CCCC(=O)O |
| Isomeric SMILES | C(CCCC(=O)O)CCCC(=O)O |
| WGK Germany | 1 |
| RTECS | CM1980000 |
| PubChem CID | 2266 |
| Molecular Weight | 188.22 |
| Beilstein | 1101094 |
Database links
| CAS Registry No. | 123-99-9 |
|---|---|
| PubChem CID | 2266 |
| ChEMBL Ligand | CHEMBL1238 |
| DrugBank Ligand | DB00548 |
| Wikipedia | Azelaic acid |
| RCSB PDB Ligand | AZ1 |
| DrugCentral Ligand | 270 |
Certificates
Certificate of Analysis(COA)
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 J2312104 | Certificate of Analysis | Oct 19, 2023 | A108440 |
| E2331185 | Certificate of Analysis | Jun 09, 2023 | A108440 |
| J2210130 | Certificate of Analysis | Oct 12, 2022 | A108440 |
| G1430043 | Certificate of Analysis | Jun 20, 2022 | A108440 |
| B2303906 | Certificate of Analysis | Nov 11, 2021 | A108440 |
| E2311097 | Certificate of Analysis | Nov 11, 2021 | A108440 |
Chemical and Physical Properties
| Solubility | Soluble in water (2.4 mg/ml at 20 °C), ethanol (5%), DMSO, methanol (70 mg/ml), and alcohol. |
|---|---|
| Sensitivity | Moisture sensitive. |
| Refractive Index | 1.4303 |
| Flash Point(°F) | 410 °F |
| Flash Point(°C) | 210 °C |
| Boil Point(°C) | 286°C |
| Melt Point(°C) | 109-111°C |
Safety and Hazards(GHS)
| Pictogram(s) | GHS07 |
|---|---|
| Signal | Warning |
| Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation |
| Precautionary Statements | P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P264:Wash hands [and …] thoroughly after handling. P362+P364:Take off contaminated clothing and wash it before reuse. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. |
| WGK Germany | 1 |
| RTECS | CM1980000 |
Related Documents
Citations of This Product
| 1. Suleixin Yang, Ka Hong Wong, Peng Hua, Chengwei He, Hua Yu, Dan Shao, Zhi Shi, Meiwan Chen. (2022) ROS-responsive fluorinated polyethyleneimine vector to co-deliver shMTHFD2 and shGPX4 plasmids induces ferroptosis and apoptosis for cancer therapy. Acta Biomaterialia, 140 (492). [PMID:34879292] |
References
| 1. A Fitton,K L Goa. (1991-05-01) Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders.. Drugs, 41 ((5)): (780-798). [PMID:1712709] |
| 2. G Hoffmann,S Aramaki,E Blum-Hoffmann,W L Nyhan,L Sweetman. (1989-04-01) Quantitative analysis for organic acids in biological samples: batch isolation followed by gas chromatographic-mass spectrometric analysis.. Clinical chemistry, 35 ((4)): (587-595). [PMID:2702744] |
| 3. K U Schallreuter,J M Wood. (1987-09-01) Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells.. Cancer letters, 36 ((3)): (297-305). [PMID:3652030] |
| 4. Q H Nguyen,T P Bui. (1995-02-01) Azelaic acid: pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne.. International journal of dermatology, 34 ((2)): (75-84). [PMID:7737781] |
| 5. F Guneral,C Bachmann. (1994-06-01) Age-related reference values for urinary organic acids in a healthy Turkish pediatric population.. Clinical chemistry, 40 ((6)): (862-866). [PMID:8087979] |
| 6. . (1993-06-21) Azelaic acid--a new topical treatment for acne.. Drug and therapeutics bulletin, 31 ((13)): (50-52). [PMID:8344141] |
| 7. G F Hoffmann,W Meier-Augenstein,S Stöckler,R Surtees,D Rating,W L Nyhan. (1993-01-01) Physiology and pathophysiology of organic acids in cerebrospinal fluid.. Journal of inherited metabolic disease, 16 ((4)): (648-669). [PMID:8412012] |
| 8. J Brasch,E Christophers. (1993-01-01) Azelaic acid has antimycotic properties in vitro.. Dermatology (Basel, Switzerland), 186 ((1)): (55-58). [PMID:8435518] |
| 9. K Graupe,W J Cunliffe,H P Gollnick,R P Zaumseil. (1996-01-01) Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports.. Cutis, 57 ((1 Suppl)): (20-35). [PMID:8654128] |
| 10. A S Breathnach. (1996-01-01) Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies.. Cutis, 57 ((1 Suppl)): (36-45). [PMID:8654129] |
| 11. P S Mackrides,A F Shaughnessy. (1996-12-01) Azelaic acid therapy for acne.. American family physician, 54 ((8)): (2457-2459). [PMID:8961845] |
| 12. V Rocamora,L Puig,J Romaní,J M de Moragas. (1999-08-04) Amelanotic lentigo maligna melanoma: report of a case and review of the literature.. Cutis, 64 ((1)): (53-56). [PMID:10431675] |
| 13. J J Russell. (2000-02-12) Topical therapy for acne.. American family physician, 61 ((2)): (357-366). [PMID:10670502] |
| 14. S H Korman,H Mandel,A Gutman. (2000-07-15) Characteristic urine organic acid profile in peroxisomal biogenesis disorders.. Journal of inherited metabolic disease, 23 ((4)): (425-428). [PMID:10896310] |
| 15. G Webster. (2000-07-18) Combination azelaic acid therapy for acne vulgaris.. Journal of the American Academy of Dermatology, 43 ((2 Pt 3)): (S47-S50). [PMID:10898830] |
| 16. J F Hermanns,L Petit,O Martalo,C Piérard-Franchimont,G Cauwenbergh,G E Piérard. (2000-10-29) Unraveling the patterns of subclinical pheomelanin-enriched facial hyperpigmentation: effect of depigmenting agents.. Dermatology (Basel, Switzerland), 201 ((2)): (118-122). [PMID:11053913] |
| 17. James Q Del Rosso. (2002-12-10) A status report on the medical management of rosacea: focus on topical therapies.. Cutis, 70 ((5)): (271-275). [PMID:12469780] |
| 18. Montserrat Morillas,Paulino Gómez-Puertas,Assia Bentebibel,Eva Sellés,Nuria Casals,Alfonso Valencia,Fausto G Hegardt,Guillermina Asins,Dolors Serra. (2002-12-25) Identification of conserved amino acid residues in rat liver carnitine palmitoyltransferase I critical for malonyl-CoA inhibition. Mutation of methionine 593 abolishes malonyl-CoA inhibition.. The Journal of biological chemistry, 278 ((11)): (9058-9063). [PMID:12499375] |
| 19. David C Liao. (2003-01-24) Management of acne.. The Journal of family practice, 52 ((1)): (43-51). [PMID:12540312] |
| 20. James Q Del Rosso. (2003-12-19) Medical treatment of rosacea with emphasis on topical therapies.. Expert opinion on pharmacotherapy, 5 ((1)): (5-13). [PMID:14680431] |
| 21. James E Frampton,Antona J Wagstaff. (2004-02-26) Azelaic acid 15% gel: in the treatment of papulopustular rosacea.. American journal of clinical dermatology, 5 ((1)): (57-64). [PMID:14979745] |
| 22. Rebat M Halder,Georgianna M Richards. (2004-04-29) Management of dyschromias in ethnic skin.. Dermatologic therapy, 17 ((2)): (151-157). [PMID:15113282] |
| 23. R M Halder,G M Richards. (2004-08-31) Topical agents used in the management of hyperpigmentation.. Skin therapy letter, 9 ((6)): (1-3). [PMID:15334278] |
| 24. Karol Burkhart Lindow. (2004-12-24) Rosacea. An overview of diagnosis and management.. Advance for nurse practitioners, 12 ((12)): (27-32). [PMID:15615217] |
| 25. Kimberly A Cayce,Amy J McMichael,Steven R Feldman. (2004-12-31) Hyperpigmentation: an overview of the common afflictions.. Dermatology nursing, 16 ((5)): (401-406). [PMID:15624705] |
| 26. John E Wolf. (2005-04-07) Present and future rosacea therapy.. Cutis, 75 ((3 Suppl)): (4-7). [PMID:15810803] |
| 27. Esther J van Zuuren,Mark A Graber. (2005-04-07) The rigor of trials evaluating Rosacea treatments.. Cutis, 75 ((3 Suppl)): (13-16). [PMID:15810805] |
| 28. Sarah Purdy. (2005-09-02) Acne vulgaris.. Clinical evidence, ((13)(13)): (2038-2059). [PMID:16135322] |
| 29. Heather L Roebuck. (2005-09-10) Face up to rosacea.. The Nurse practitioner, 30 ((9)): (24-30). [PMID:16151303] |
| 30. Valerie D Callender. (2005-09-17) Considerations for treating acne in ethnic skin.. Cutis, 76 ((2 Suppl)): (19-23). [PMID:16164153] |
| 31. Jennie B Nally,Diane S Berson. (2006-02-14) Topical therapies for rosacea.. Journal of drugs in dermatology : JDD, 5 ((1)): (23-26). [PMID:16468288] |
| 32. Zoe Diana Draelos. (2006-03-29) The rationale for advancing the formulation of azelaic acid vehicles.. Cutis, 77 ((2 Suppl)): (7-11). [PMID:16566282] |
| 33. Boni Elewski,Diane Thiboutot. (2006-03-29) A clinical overview of azelaic acid.. Cutis, 77 ((2 Suppl)): (12-16). [PMID:16566283] |
| 34. James Q Del Rosso. (2006-03-29) The use of topical azelaic acid for common skin disorders other than inflammatory rosacea.. Cutis, 77 ((2 Suppl)): (22-24). [PMID:16566285] |
| 35. Wolf-Ingo Worret,Joachim W Fluhr. (2006-04-28) [Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid].. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 4 ((4)): (293-300). [PMID:16638058] |
| 36. Rosemarie H Liu,Molly K Smith,Sameh A Basta,Evan R Farmer. (2006-08-23) Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials.. Archives of dermatology, 142 ((8)): (1047-1052). [PMID:16924055] |
| 37. Greg Goodman. (2006-09-14) Managing acne vulgaris effectively.. Australian family physician, 35 ((9)): (705-709). [PMID:16969442] |
| 38. Sarah Purdy. (2006-09-16) Acne vulgaris.. Clinical evidence, ((15)(15)): (2183-2201). [PMID:16973084] |
| 39. Aditya K Gupta,Melissa D Gover,Keyvan Nouri,Susan Taylor. (2006-11-14) The treatment of melasma: a review of clinical trials.. Journal of the American Academy of Dermatology, 55 ((6)): (1048-1065). [PMID:17097400] |
| 40. Esther J van Zuuren,Aditya K Gupta,Melissa D Gover,Mark Graber,Sally Hollis. (2006-12-28) Systematic review of rosacea treatments.. Journal of the American Academy of Dermatology, 56 ((1)): (107-115). [PMID:17190628] |
| 41. Phedias Diamandis,Jan Wildenhain,Ian D Clarke,Adrian G Sacher,Jeremy Graham,David S Bellows,Erick K M Ling,Ryan J Ward,Leanne G Jamieson,Mike Tyers,Peter B Dirks. (2007-04-10) Chemical genetics reveals a complex functional ground state of neural stem cells.. Nature chemical biology, 3 ((5)): (268-273). [PMID:17417631] |
| 42. Aditya K Gupta,Melissa D Gover. (2007-05-03) Azelaic acid (15% gel) in the treatment of acne rosacea.. International journal of dermatology, 46 ((5)): (533-538). [PMID:17472690] |
| 43. Diane Thiboutot. (2008-02-06) Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris.. Journal of drugs in dermatology : JDD, 7 ((1)): (13-16). [PMID:18246693] |
| 44. Harald Gollnick,Alison Layton. (2008-09-23) Azelaic acid 15% gel in the treatment of rosacea.. Expert opinion on pharmacotherapy, 9 ((15)): (2699-2706). [PMID:18803456] |
| 45. Arun Sreekumar,Laila M Poisson,Thekkelnaycke M Rajendiran,Amjad P Khan,Qi Cao,Jindan Yu,Bharathi Laxman,Rohit Mehra,Robert J Lonigro,Yong Li,Mukesh K Nyati,Aarif Ahsan,Shanker Kalyana-Sundaram,Bo Han,Xuhong Cao,Jaeman Byun,Gilbert S Omenn,Debashis Ghosh,Subramaniam Pennathur,Danny C Alexander,Alvin Berger,Jeffrey R Shuster,John T Wei,Sooryanarayana Varambally,Christopher Beecher,Arul M Chinnaiyan. (2009-02-13) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.. Nature, 457 ((7231)): (910-914). [PMID:19212411] |
| 46. Joachim W Fluhr,Klaus Degitz. (2010-05-28) [Antibiotics, azelaic acid and benzoyl peroxide in topical acne therapy].. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 8 Suppl 1 (S24-S30). [PMID:20482689] |
| 47. Ji Sun Yu,An Keun Kim. (2010-09-11) Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells.. Journal of biomedical science, 17 Suppl 1 (S45-S45). [PMID:20804622] |
| 48. Wolfram Gronwald,Matthias S Klein,Raoul Zeltner,Bernd-Detlef Schulze,Stephan W Reinhold,Markus Deutschmann,Ann-Kathrin Immervoll,Carsten A Böger,Bernhard Banas,Kai-Uwe Eckardt,Peter J Oefner. (2011-03-11) Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine.. Kidney international, 79 ((11)): (1244-1253). [PMID:21389975] |
| 49. Esther J van Zuuren,Sharon Kramer,Ben Carter,Mark A Graber,Zbys Fedorowicz. (2011-03-18) Interventions for rosacea.. The Cochrane database of systematic reviews, ((3)): (CD003262-CD003262). [PMID:21412882] |
| 50. Nicola Castellucci,Giuseppe Falini,Gaetano Angelici,Claudia Tomasini. (2011-04-14) Formation of gels in the presence of metal ions.. Amino acids, 41 ((3)): (609-620). [PMID:21487726] |
| 51. Leon H Kircik. (2011-06-04) Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study.. Journal of drugs in dermatology : JDD, 10 ((6)): (586-590). [PMID:21637899] |
| 52. Ronald G Wheeland,Sunil Dhawan. (2011-06-04) Evaluation of self-treatment of mild-to-moderate facial acne with a blue light treatment system.. Journal of drugs in dermatology : JDD, 10 ((6)): (596-602). [PMID:21637900] |
| 53. Changgeng Liu,Jie Gan,Yang Zhang,Miao Liang,Xi Shu,Jinian Shu,Bo Yang. (2011-08-30) Heterogeneous reaction of suspended phosmet particles with NO3 radicals.. The journal of physical chemistry. A, 115 ((39)): (10744-10748). [PMID:21870875] |
| 54. A Parodi,F Drago,S Paolino,E Cozzani,R Gallo. (2011-09-13) [Treatment of rosacea].. Annales de dermatologie et de venereologie, 138 Suppl 2 (S158-S162). [PMID:21907876] |
| 55. James Q Del Rosso,Neal Bhatia. (2011-09-16) Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application.. Cutis, 88 ((2)): (67-72). [PMID:21916272] |
| 56. Vaneeta M Sheth,Amit G Pandya. (2011-09-17) Melasma: a comprehensive update: part II.. Journal of the American Academy of Dermatology, 65 ((4)): (699-714). [PMID:21920242] |
| 57. Nan Li,Xiaohong Wu,Weibu Jia,Michelle C Zhang,Fengping Tan,Jerry Zhang. (2011-11-25) Effect of ionization and vehicle on skin absorption and penetration of azelaic acid.. Drug development and industrial pharmacy, 38 ((8)): (985-994). [PMID:22111946] |
| 58. Susan Farshi. (2011-12-14) Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma.. Journal of cosmetic dermatology, 10 ((4)): (282-287). [PMID:22151936] |
| 59. Zhichao Liu,Qiang Shi,Don Ding,Reagan Kelly,Hong Fang,Weida Tong. (2011-12-24) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).. PLoS computational biology, 7 ((12)): (e1002310-e1002310). [PMID:22194678] |
| 60. Maria Vinaixa,Miguel Angel Rodriguez,Sara Samino,Marta Díaz,Antoni Beltran,Roger Mallol,Cinta Bladé,Lourdes Ibañez,Xavier Correig,Oscar Yanes. (2011-12-24) Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.. PloS one, 6 ((12)): (e29052-e29052). [PMID:22194988] |
| 61. Pei-Wen Hsieh,Saleh A Al-Suwayeh,Chia-Lang Fang,Chwan-Fwu Lin,Chun-Che Chen,Jia-You Fang. (2012-04-04) The co-drug of conjugated hydroquinone and azelaic acid to enhance topical skin targeting and decrease penetration through the skin.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 81 ((2)): (369-378). [PMID:22469554] |
| 62. Merve Aytekin,R Neslihan Gursoy,Semra Ide,Elif H Soylu,Sueda Hekimoglu. (2012-04-07) Formulation and characterization of liquid crystal systems containing azelaic acid for topical delivery.. Drug development and industrial pharmacy, 39 ((2)): (228-239). [PMID:22480294] |
| 63. Neal D Bhatia,James Q Del Rosso. (2012-07-11) Optimal management of papulopustular rosacea: rationale for combination therapy.. Journal of drugs in dermatology : JDD, 11 ((7)): (838-844). [PMID:22777226] |
| 64. Maria Zoeller,Nadja Stingl,Markus Krischke,Agnes Fekete,Frank Waller,Susanne Berger,Martin J Mueller. (2012-07-24) Lipid profiling of the Arabidopsis hypersensitive response reveals specific lipid peroxidation and fragmentation processes: biogenesis of pimelic and azelaic acid.. Plant physiology, 160 ((1)): (365-378). [PMID:22822212] |
| 65. Tsutomu Matsubara,Naoki Tanaka,Kristopher W Krausz,Soumen K Manna,Dong Wook Kang,Erik R Anderson,Hans Luecke,Andrew D Patterson,Yatrik M Shah,Frank J Gonzalez. (2012-11-13) Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis.. Cell metabolism, 16 ((5)): (634-644). [PMID:23140643] |
| 66. Hamidreza Pazoki-Toroudi,Shahab Babakoohi,Mohammad Ali Nilforoushzadeh,Mansour Nassiri-Kashani,Mohammad Shizarpour,Marjan Ajami,Rouhollah Habibey,Bardia Sadr,Mehdi Rashighi-Firoozabadi,Alireza Firooz. (2012-11-21) Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia.. Skinmed, 10 ((5)): (276-282). [PMID:23163069] |
| 67. Robyn S Fallen,Melinda Gooderham. (2012-12-12) Rosacea: update on management and emerging therapies.. Skin therapy letter, 17 ((10)): (1-4). [PMID:23223767] |
| 68. Stefania Briganti,Enrica Flori,Arianna Mastrofrancesco,Daniela Kovacs,Emanuela Camera,Matteo Ludovici,Giorgia Cardinali,Mauro Picardo. (2013-01-03) Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts: possible implication of PPARγ.. Experimental dermatology, 22 ((1)): (41-47). [PMID:23278893] |
| 69. Shanmugam Muthulakshmi,Ramalingam Saravanan. (2013-01-31) Protective effects of azelaic acid against high-fat diet-induced oxidative stress in liver, kidney and heart of C57BL/6J mice.. Molecular and cellular biochemistry, 377 ((1-2)): (23-33). [PMID:23361364] |
| 70. Nitin Chauhan,David A F Ellis. (2013-02-02) Rosacea: pathophysiology and management principles.. Facial plastic surgery clinics of North America, 21 ((1)): (127-136). [PMID:23369595] |
| 71. Alan R Shalita,Ronald Falcon,Alan Olansky,Patricia Iannotta,Arash Akhavan,Doris Day,Anthony Janiga,Prashant Singri,John E Kallal. (2013-02-05) Inflammatory acne management with a novel prescription dietary supplement.. Journal of drugs in dermatology : JDD, 11 ((12)): (1428-1433). [PMID:23377512] |
| 72. J Mark Jackson,Leon H Kircik,Douglas J Lorenz. (2013-04-03) Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea.. Journal of drugs in dermatology : JDD, 12 ((3)): (292-298). [PMID:23545911] |
| 73. Heather C Woolery-Lloyd,Jonette Keri,Stefan Doig. (2013-05-09) Retinoids and azelaic acid to treat acne and hyperpigmentation in skin of color.. Journal of drugs in dermatology : JDD, 12 ((4)): (434-437). [PMID:23652891] |
| 74. Alvin B Coda,Tissa Hata,Jeremiah Miller,David Audish,Paul Kotol,Aimee Two,Faiza Shafiq,Kenshi Yamasaki,Julie C Harper,James Q Del Rosso,Richard L Gallo. (2013-07-23) Cathelicidin, kallikrein 5, and serine protease activity\xa0is inhibited during treatment of rosacea with azelaic acid 15% gel.. Journal of the American Academy of Dermatology, 69 ((4)): (570-577). [PMID:23871720] |
| 75. Xiaoling Zang,Christina M Jones,Tran Q Long,María Eugenia Monge,Manshui Zhou,L DeEtte Walker,Roman Mezencev,Alexander Gray,John F McDonald,Facundo M Fernández. (2014-06-13) Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics.. Journal of proteome research, 13 ((7)): (3444-3454). [PMID:24922590] |
| 76. Yosuke Fukutani,Ayaka Hori,Satoshi Tsukada,Ryoichi Sato,Jun Ishii,Akihiko Kondo,Hiroaki Matsunami,Masafumi Yohda. (2014-12-03) Improving the odorant sensitivity of olfactory receptor-expressing yeast with accessory proteins.. Analytical biochemistry, 471 (1-8). [PMID:25449303] |
| 77. Chaemyeong Lee,Sang-Yup Lee. (2015-02-07) Mussel-inspired bolaamphiphile sticky self-assemblies for the preparation of magnetic nanoparticles.. Colloids and surfaces. B, Biointerfaces, 127 (89-95). [PMID:25658196] |
| 78. Fei Li,Xiu-Wei Yang,Kristopher W Krausz,Robert G Nichols,Wei Xu,Andrew D Patterson,Frank J Gonzalez. (2015-02-26) Modulation of colon cancer by nutmeg.. Journal of proteome research, 14 ((4)): (1937-1946). [PMID:25712450] |
| 79. Zhonghua Wang,Yajie Zheng,Baoxin Zhao,Yanping Zhang,Zhe Liu,Jing Xu,Yanhua Chen,Zhao Yang,Fenfen Wang,Huiqing Wang,Jiuming He,Ruiping Zhang,Zeper Abliz. (2015-05-21) Human metabolic responses to chronic environmental polycyclic aromatic hydrocarbon exposure by a metabolomic approach.. Journal of proteome research, 14 ((6)): (2583-2593). [PMID:25990285] |
| 80. Sanket M Shah,Mukul Ashtikar,Ankitkumar S Jain,Dinesh T Makhija,Yuvraj Nikam,Rajiv P Gude,Frank Steiniger,Aarti A Jagtap,Mangal S Nagarsenker,Alfred Fahr. (2015-05-24) LeciPlex, invasomes, and liposomes: A skin penetration study.. International journal of pharmaceutics, 490 ((1-2)): (391-403). [PMID:26002568] |
| 81. Anne Krog Ingerslev,Ibrahim Karaman,Murat Bağcıoğlu,Achim Kohler,Peter Kappel Theil,Knud Erik Bach Knudsen,Mette Skou Hedemann. (2015-07-03) Whole Grain Consumption Increases Gastrointestinal Content of Sulfate-Conjugated Oxylipins in Pigs - A Multicompartmental Metabolomics Study.. Journal of proteome research, 14 ((8)): (3095-3110). [PMID:26133160] |
| 82. Maryam Goudarzi,Waylon M Weber,Juijung Chung,Melanie Doyle-Eisele,Dunstana R Melo,Tytus D Mak,Steven J Strawn,David J Brenner,Raymond Guilmette,Albert J Fornace. (2015-08-12) Serum Dyslipidemia Is Induced by Internal Exposure to Strontium-90 in Mice, Lipidomic Profiling Using a Data-Independent Liquid Chromatography-Mass Spectrometry Approach.. Journal of proteome research, 14 ((9)): (4039-4049). [PMID:26262552] |
| 83. A Mayer-da-Silva,H Gollnick,M Detmar,J Gassmüller,A Parry,R Müller,C E Orfanos. (1989-01-01) Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. An in vivo and in vitro study.. Acta dermato-venereologica. Supplementum, 143 (20-30). [PMID:2475995] |
| 84. D Stamatiadis,M C Bulteau-Portois,I Mowszowicz. (1988-11-01) Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid.. The British journal of dermatology, 119 ((5)): (627-632). [PMID:3207614] |
| 85. J R Gibson. (1997-12-11) Azelaic acid 20% cream (AZELEX) and the medical management of acne vulgaris.. Dermatology nursing, 9 ((5)): (339-344). [PMID:9392765] |
| 86. John E Wolf. (2004-02-13) The role of topical metronidazole in the treatment of rosacea.. Cutis, 73 ((1 Suppl)): (19-28). [PMID:14959942] |
| 87. Alan B Fleischer. (2006-03-29) The evolution of azelaic acid.. Cutis, 77 ((2 Suppl)): (4-6). [PMID:16566281] |
| 88. Zhigang Chen,Huili Chen,He Hu,Mengxiao Yu,Fuyou Li,Qiang Zhang,Zhiguo Zhou,Tao Yi,Chunhui Huang. (2008-02-19) Versatile synthesis strategy for carboxylic acid-functionalized upconverting nanophosphors as biological labels.. Journal of the American Chemical Society, 130 ((10)): (3023-3029). [PMID:18278910] |
| 89. Chizuru Sato,Norikuni Oka,Kensuke Nabeta,Hideyuki Matsuura. (2011-04-23) Cellulase applied to the leaves of sweet pepper (Capsicum annuum L. var. grossum) upregulates the production of salicylic and azelaic acids.. Bioscience, biotechnology, and biochemistry, 75 ((4)): (761-763). [PMID:21512237] |
| 90. Hamidreza Pazoki-Toroudi,Mohamad Ali Nilforoushzadeh,Marjan Ajami,Fariba Jaffary,Nahid Aboutaleb,Mansour Nassiri-Kashani,Alireza Firooz. (2011-05-27) Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris.. Cutaneous and ocular toxicology, 30 ((4)): (286-291). [PMID:21612319] |
| 91. C Schnopp,M Mempel. (2011-09-13) Acne vulgaris in children and adolescents.. Minerva pediatrica, 63 ((4)): (293-304). [PMID:21909065] |
| 92. Ali Awsat Mellati,Faranak Sharifi,Mohsen Sajadinejad,Davood Sohrabi,Saeideh Mazloomzadeh. (2011-10-26) The relationship between retinol-binding protein 4 levels, insulin resistance, androgen hormones and polycystic ovary syndrome.. Scandinavian journal of clinical and laboratory investigation, 72 ((1)): (39-44). [PMID:22023042] |
| 93. Suleixin Yang, Ka Hong Wong, Peng Hua, Chengwei He, Hua Yu, Dan Shao, Zhi Shi, Meiwan Chen. (2022) ROS-responsive fluorinated polyethyleneimine vector to co-deliver shMTHFD2 and shGPX4 plasmids induces ferroptosis and apoptosis for cancer therapy. Acta Biomaterialia, 140 (492). [PMID:34879292] |